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ARTICLE
Mutational signatures in tumours induced by high
and low energy radiation in Trp53 deficient mice
Yun Rose Li1,2,10, Kyle D. Halliwill1,3,10, Cassandra J. Adams1,4,10, Vivek Iyer5, Laura Riva5, Rashid Mamunur5,
Kuang-Yu Jen1,6, Reyno del Rosario1, Erik Fredlund1,7, Gillian Hirst 1, Ludmil B. Alexandrov 8,
David Adams 5* & Allan Balmain 1,9*
Ionising radiation (IR) is a recognised carcinogen responsible for cancer development in
patients previously treated using radiotherapy, and in individuals exposed as a result of
accidents at nuclear energy plants. However, the mutational signatures induced by distinct
types and doses of radiation are unknown. Here, we analyse the genetic architecture of
mammary tumours, lymphomas and sarcomas induced by high (56Fe-ions) or low (gamma)
energy radiation in mice carrying Trp53 loss of function alleles. In mammary tumours, high-
energy radiation is associated with induction of focal structural variants, leading to genomic
instability and Met amplification. Gamma-radiation is linked to large-scale structural variants
and a point mutation signature associated with oxidative stress. The genomic architecture of
carcinomas, sarcomas and lymphomas arising in the same animals are significantly different.
Our study illustrates the complex interactions between radiation quality, germline Trp53
deficiency and tissue/cell of origin in shaping the genomic landscape of IR-induced tumours.
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Carcinogens in the environment contribute to cancerdevelopment by inducing DNA damage, resulting inspecific patterns of mutations that can be diagnostic for
the causative carcinogenic agent. Such “mutational signatures”
help us to understand and quantify the impact of potential car-
cinogens on human tumour DNA, and can provide information
on the mechanisms by which these agents act. Mutational sig-
natures have been detected in thousands of human cancers1,
as well as in mouse models of chemical carcinogen-induced
tumours2,3. In contrast, while ionizing radiation through medical
exposures has been associated with increased risk of secondary
malignancies4, we presently have no detailed knowledge of the
types of signatures that are induced by this common source of
DNA damage.
Environmental and therapeutic IR can exist in a number of
different forms, depending on radiation quality and energy, which
impact how radiation interacts with biological target molecules,
such as DNA. High energy gamma rays or photons are the most
commonly used form of therapeutic IR and occur naturally in the
earth’s atmosphere due to radioactive decay or are secondary to
the action of cosmic rays. In contrast, heavy-ion or high linear
energy transfer (LET) radiation is characterised by charged, high
energy particles (protons, Fe-ions) and accounts for approxi-
mately 1% of cosmic rays5,6. Individuals at highest risk from
radiation exposures are patients being treated for cancer by
localised radiotherapy, most often using fractionated high doses
of gamma rays to focally targeted sites. However lower doses
of radiation also have biological effects, the consequences of
which have not been adequately investigated in terms of possible
genomic changes.
In fact, the exact mechanisms through which radiation induces
DNA damage and its impact on the genomic landscape of
radiation-induced malignancies are not well-established and have
been highly controversial. Although there is general support for a
direct model in which IR causes single or double strand breaks by
direct collision with DNA, indirect models have also been pro-
posed by which IR interacts with other molecules (e.g., water)
to increase DNA damage secondary to free radical formation, or
impacts the normal tissue microenvironment to promote cyto-
kine production and transformation through mechanisms that
are presently unclear7. Radiation has been proposed to cause
transformation due to a “bystander effect” even in cells that have
not been directly traversed by radiation particles8,9 but the role
of this mechanism in vivo has not been established. Resolution of
these questions is important not only for our understanding of
mechanisms of carcinogenesis after therapeutic or accidental
exposure to ionizing radiation, but also for assessment of cancer
risk as a result of occupational exposure, or, increasingly, as a
consequence of longer term exposure to cosmic radiation during
space flights10,11.
Characterising these mechanisms in human tumours is impe-
ded by limited sample size, germline heterogeneity, complex
environmental exposures and uncertainty in the dose, duration,
frequency and quality of radiation exposure. Thus, the use of
appropriate model systems that properly recapitulate the effects
of RT in cells and animal models is pivotal. Indeed, high and low
LET studies have been carried out on cells in vitro and in lower
organisms, and the types of changes seen depend on radiation
quality (reviewed in Durante & Cucinotta)12. Specifically, high
LET radiation is associated with intense focal damage caused by
the traversal of heavy ions through the nucleus13–15. In contrast,
gamma radiation causes more indirect DNA damage, diffuse
patterns of H2AX foci, and increased oxidative stress16.
Trp53, a gene also known as the guardian of the genome17, is
critical in affecting the cellular outcome following DNA
damage18,19. Human patients with germline TP53 mutations
are highly tumour-prone20,21, and genomic studies have linked
germline TP53 deficiency to development of genomically
unstable tumours with a high incidence of chromothripsis22–25.
To develop a deeper understanding of the effects of radiation on
tumour DNA integrity, we use mouse strains with partial
germline deficiency in Trp53 function, i.e., mice hemizygous for
Trp53 (Trp53(+/−)), or homozygous for the Delta P Trp53 allele
(Trp53(DP/DP)); hereafter Trp53ΔP). The Trp53(+/−) strain is
highly susceptible to both spontaneous and radiation-induced
(4 Gy gamma) lymphoma development, while the Trp53ΔP
strain develops a wider range of tumours after exposure to the
same radiation dose26–28. The Trp53ΔP mouse carries a dele-
tion in the N-terminal proline-rich domain (PRD) of TP53, a
region that is important in the regulation of human TP53
activity and stability. A common germline polymorphism at
codon 72 in this region has been associated with altered cancer
risk in humans29,30.
In this study, we breed both strains of mice on to the same
genetic background (FVB/N), and expose the animals to a rela-
tively low dose (50 cGy) of gamma (low LET) or Fe-ion (high
LET) radiation to explore the effects on susceptibility to tumour
development in different tissues. In particular, the 50 cGy dose of
Fe-ions is studied as it has been proposed by NASA and other
previous studies as a realistic dose to which astronauts may be
exposed during exploratory space missions31–33. We demonstrate
that this low radiation dose results in the development of a wide
range of malignancies in the context of germline Trp53 deficiency,
but particularly in a high incidence of mammary carcinomas
and angiosarcomas, which are also common radiation-associated
malignancies in humans. Whole-genome sequencing of mam-
mary tumours and whole-exome sequencing of a wider spectrum
of IR-induced tumours reveals complex point mutational sig-
natures and patterns of structural rearrangements in tumour
genomes that are associated with radiation quality, as well as
germline Trp53 status and tumour histology.
Results
Low dose radiation-induced tumours in Trp53-deficient mice.
We previously showed that Trp53ΔP mice in a mixed 129/C57BL6
background were highly sensitive to development of several tumour
types after a single exposure to whole body gamma radiation, but
had a low spontaneous rate of tumour development26. We exposed
238 FVB/N mice that were Trp53 WT, hemizygous (Trp53+/−) or
homozygous for the Delta P Trp53 allele (Trp53ΔP), to a single dose
of either 56Fe-ion (600MeV/amu) or gamma radiation. Most ani-
mals were exposed to a dose of 50 cGy of either radiation type, but a
few received lower or higher doses (Supplementary Data 1 and
Suppementary Table 1). Animals were followed for >400 days to
monitor tumour development; a subset of sham irradiated controls
was also included (Fig. 1a). A total of 160 mice developed at least
one of several histological types of tumour after radiation exposure,
most commonly in the mammary glands, skin, lung and lymphoid
tissue (Fig. 1b, c). As expected, wild type mice were generally
resistant to development of tumours induced by radiation (Fig. 1d),
but a few animals were sacrificed early, predominantly those that
developed tumours after exposure to 56Fe-ions (Fig. 1e). Overall,
Trp53ΔP animals were much more likely to develop carcinomas in
the skin, mammary gland, and other tissues, versus other histologic
subtypes, (P= 3.63e−05, chi-sq test; Fig. 1b, c).
The most common site of tumour development was the
mammary gland, regardless of radiation quality or Trp53 germline
status (Fig. 1b). There were a number of histological subtypes,
including adenocarcinomas (ADC), squamous cell carcinomas
(SCC), spindle cell carcinomas (SPN), and sarcomas (SAR),
including angiosarcomas (Fig. 1c). Notably, in humans, sarcomas
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and angiosarcomas appear to show a disproportionally higher
incidence in patients with a history of prior radiation therapy to
the chest or thorax34. Compared to other models of radiation-
induced tumours in Trp53-deficient mice (129/Sv strain, 4 Gy
gamma ray exposure) where the predominant tumour types were
lymphomas and sarcomas27,35, the present model (i.e., FVB/50
cGy) more closely mimics the spectrum of radiation-induced
tumours observed in humans.
Radiation quality had a significant impact on tumour latency
and disease-free survival (DFS), as animals exposed to Fe-ion
radiation survived on average 287 days, as compared to gamma
radiation (358 days) (univariate Cox-Proportional Hazard analysis,
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HR= 2.36, P < 1.94e−06; Fig. 1d–f). No obvious effect on survival
was attributable to mouse strain genotype (Trp53(+/−) or Trp53ΔP,
Fig. 1d). On analysis by disease site, mammary, skin, and lung
tumours all had a shorter latency following exposure to 56Fe
radiation compared to gamma. In contrast, a different pattern was
seen for lymphomas, which developed earlier after exposure to
gamma radiation (Fig. 1f, lower right panel).
Mutational signatures in radiation-induced tumours. We per-
formed whole-genome sequencing (WGS) of a focused cohort of
21 mammary tumours from animals of Trp53+/− or Trp53ΔP
backgrounds exposed to 50 cGy Fe-ion or gamma radiation
(Supplementary Table 1). The overall frequency of point muta-
tions or single nucleotide variants (SNVs) was low (median=
1.16, mean= 2.009; range 0.62–14.6 SNVs/Mb), considerably less
than observed in chemically-induced mouse tumours of the same
genetic background2,3. The rate did not differ significantly
according to tumour type or radiation quality (P= 0.52 and P=
0.92, respectively, Fisher’s Exact test; Supplementary Fig. 1A). The
dearth of point mutations in these samples, most of which
mapped to non-coding regions of the genome (Supplementary
Fig. 1C and D), is consistent with that reported previously in
radiation-associated human tumours4.
As SNV mutational signatures can provide genomic evidence
for the aetiology of tumour initiation and progression, we next
evaluated whether tumours that result from exposures to different
radiation qualities show distinct point mutation patterns1,36,37.
We hypothesised that a signature of reactive oxygen species
(ROS)-related DNA damage may be observed as an indirect
consequence of IR exposure. IR is known to generate free
radicals38, which can in turn damage DNA by causing the
formation of 8-Oxo-guanine adducts. We addressed this question
by two different approaches: searching for de novo mutational
signatures using Nonnegative Matrix Factorisation (NMF), and
analysis of cosine similarity to existing trinucleotide mutational
signatures in a wide range of human cancers37. When we
performed de novo mutational signature extraction using WGS-
derived SNVs, we observed 3 independent signatures (Fig. 2a).
Signature SNV A was enriched for G > T (C > A) substitutions
which can be generated by misrepair of 8-oxo-guanine adducts38.
This signature is consistent with the previously described human
COSMIC signature 18, which was previously reported to be
associated with oxidative DNA damage due to ROS39,40.
Signature SNV B resembles the pattern of human signature 5,
which is one of the clock signatures and is comprised of C > T
and T > C transitions37, while signature SNV C had no obvious
similarity with other Cosmic signatures.
Signature deconvolution using the established human COSMIC
mutational signatures36,37, revealed a strong cosine similarity with
several human signatures, including signature 18, clock signature
5, and signature 3, which is found in most mouse mammary
carcinomas and is associated with defects in homologous
recombination (Fig. 2b). This process is critical for the repair
of double-stranded breaks induced by RT37. Signature 18 (red,
Fig. 2b) was variable across samples, but was preferentially
enriched in tumours induced by gamma radiation, compared to
those induced by 56Fe-ions (p < 0.032, Fisher’s Exact test). While
these data are based on a relatively small sample size (12 gamma-
induced and 9 heavy ion-induced tumours), the results are
consistent with the hypothesis that 50 cGy gamma radiation
results in higher levels of ROS than 50 cGy high LET radiation.
Indel signatures in radiation-induced tumours. We performed
de novo INDEL mutational signature extraction from the 21
WGS samples, identifying three unique INDEL signatures: A, B
and C (Fig. 2c and Supplementary Fig. 2)1. Signature INDEL-A
was enriched for microhomology domain-associated deletions
and repeat-mediated insertions, while signature INDEL-B was
enriched in single base simple Thymidine insertions and dele-
tions. Both signatures were observed in the majority of samples
without clear association with Trp53 genotype. Signature INDEL-
C was identified in only 2 samples and was not strongly enriched
for any particular INDEL class.
Unsupervised hierarchical clustering of both INDEL and SNV
signatures (Fig. 2d) revealed some significant correlations
between specific combinations of INDELs and SNVs. The high
ROS SNV signature (human signature 18) that was enriched in
samples induced by exposure to gamma radiation (Fig. 2b)
showed a significant correlation with signature INDEL A (P=
0.017, Fisher’s Exact test) (Fig. 2d). Interestingly, Sharma et al.
have proposed that ROS-induced damage can cause oxidatively
induced clustered DNA lesions that lead to double strand
breaks and deletions caused by error-prone repair by the non-
homologous end-joining (NHEJ) pathway41. It is therefore
possible that the co-occurrence of SNV signature 18 and
signature INDEL A is related to relatively higher levels of ROS
induced by gamma rays, but further detailed studies would be
required to confirm this association.
Structural rearrangements in radiation-induced tumour gen-
omes. In contrast to the low SNV rate, genomes from radiation-
induced tumours bore frequent structural rearrangements.
Figure 3 shows the patterns of genomic alterations in mammary
tumours arranged by sample ID (Fig. 3a) or by chromosome
(Fig. 3b) based on whole-genome sequencing. We identified a
mean of 27 rearrangements per tumour. These large structural
variants (SVs) were enriched in deletions (mean n= 11.3/sample)
as opposed to insertions (1.52) or inversions (6.1). A total of 74
intrachromosomal (ITX) and 66 interchromosomal complex
translocations (CTX) were observed. The distributions of muta-
tions across samples and chromosomes were non-homogeneous.
Fig. 1 Tumour histology and survival in observed RT-induced malignancies. a Study schema showing that animals of different germline Trp53 status
(Trp53+/−, ΔP (Trp53ΔP), and WT) receiving radiation of different qualities (Gamma, Fe-Ion and Sham) developed a range of different tumour types that
were harvested and studied for pathology and selectively sequenced by whole-exome (WES) or whole-genome (WGS) platforms. b Tissue distribution of
different tumour types following whole body radiation exposure, as a function of radiation quality and germline Trp53 status. Independent tumours from
animals (with clearly independent primaries by histology) were separately counted. SFT soft tissues, LNS Lymph nodes, Repro, reproductive organs, GI
gastrointestinal tract. N= 479. c Incidence of different pathologic tumour types by radiation quality and germline Trp53 status. Most adenocarcinomas and
sarcomas were in the mammary gland, and most squamous carcinomas in the skin. N= 479. d Tumour-free survival (TFS) of animals by germline
genotype (top) and radiation quality (bottom). An event was defined death due to tumour confirmed by pathology and dissection and/or visible tumour
requiring euthanasia. N= 238. e Interaction of genotype and radiation quality on TFS. Wildtype animals with exposure to Fe-Ion have a substantial risk of
malignancy as compared to animals with gamma exposure. N= 238. f TFS related to different tumour disease sites. Survival was reduced in animals
developing skin, mammary or lung tumours after exposure to Fe ions compared to gamma radiation, but this was reversed for lymphomas, which showed
earlier onset and were preferentially induced by gamma radiation exposure. N= 238.
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SVs as well as smaller INDELs were clustered in some tumours
(Fig. 3a) and also were located predominantly in a few chromo-
somes including chromosomes 1, 6, 11 and 17 (Fig. 3b).
Carcinomas were significantly more enriched in large scale SVs
than sarcomas (P < 0.01, Fisher’s Exact test; Fig. 3c top vs lower
panels). Furthermore, inversion rearrangements were more com-
mon in carcinomas from Trp53+/− than from Trp53ΔP mice, and
in particular carcinomas in mice exposed to gamma radiation
carried 68.2% of all inversions (P < 1 × 10−4, Fisher’s Exact test;
Fig. 3c (top right panel) and 3D). Prior work has shown that
distinct mutational processes can impact the observed frequency of
focal versus non-focal rearrangements42. We classified structural
variants into focal and non-focal SV types and examined the
differences in the distribution of focal SVs (including mixed
chromosomes containing complex regions of copy number gains
and losses) as opposed to non-focal rearrangements (including
whole chromosome aneuploidy (see Methods section), as a function
of germline Trp53 genotype, histological subtype and radiation
quality (Fig. 3d). In addition to showing that SVs are rare in
sarcomas, this analysis showed that 56Fe-ion exposure was more
likely to result in focal deletions and insertions, whereas non-focal
SVs or whole chromosome aneuploidy were enriched in tumours
induced by gamma radiation or from Trp53+/− mice (Fig. 3d).
Most SVs were small (<100 Kb) although clusters of larger SVs were
observed in several chromosomes (Fig. 3e). We conclude that the
type of radiation to which the mice are exposed has differential
effects on the nature of the resulting genomic alterations, with heavy
ion, high LET radiation linked to more focal changes, particularly in
Trp53ΔP mice, and low LET gamma radiation associated with
larger scale chromosome alterations, particularly in Trp53 hetero-
zygous mice. The data therefore demonstrate a strong interaction
between germline Trp53 status and radiation quality in determining
patterns of genomic instability.
Gene copy number changes in radiation-induced tumours.
Analysis of gene copy number variation (CNVs) in the WGS data
revealed striking patterns of gains or losses across many different
chromosomes (Supplementary Fig. 3). Copy number gains were
seen frequently on chromosomes 5, 6 and 15, while losses pre-
dominated on chromosomes 4, 9, 12 and 18. Interestingly, some
individual tumours showed patterns dominated mainly by CNV
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Fig. 2 SNV and INDEL signatures in RT-induced mammary tumours. a De novo SNV signature extraction using NMF identified three distinct point
mutation signatures, referenced to here and in the text as “A”, “B” and “C”. N= 21. b Deconvolution of the mutation signatures into known Cosmic
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contribution of the signature 18 “ROS” to total mutations in each sample, and these are relatively enriched in tumours induced by gamma radiation
compared to 56Fe ions (P < 0.032). Pale blue denotes contribution from variants not explained by known Cosmic signatures. N= 21. c Relative contribution
of each insertion/deletion mutation type in the three INDEL signatures identified in the mammary tumour samples. See Supplementary Fig. 2 for a
breakdown of all categories of INDEL types. “Del_B”= 1 bp deletion, “Ins_B”= 1 bp insertion, where “C” or “T” describes whether cytosine or thymidine was
deleted at that position, “MH”=microhomology domain and “REP”= >1 bp deletion or insertion at repeats. N= 21. d Relationship between INDEL
signatures and SNV signatures. Hierarchical clustering of both INDEL signatures and SNV signatures demonstrates an enrichment of de novo INDEL
signature A (left) and SNV signature 18 (ROS, right) in samples induced by exposure to gamma radiation compared to those induced by 56Fe ions
(P < 0.032). N= 21.
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(SNVs), ITX: Intrachromosomal translocation, INV: Inversion rearrangements, INS: insertion rearrangements, DEL: deletion rearrangements, CTX: Complex
or inter-chromosomal translocations, Complex: Complex insertions. Number of base pairs impacted by each mutation type is plotted on the y-axis in
logarithmic scale. b Distribution of mutations (as in a) in each WGS mammary tumour sample sorted by chromosome. Each column corresponds to one
unique sample and each facet box encompasses one chromosome. Large scale variants were found mainly in chromosomes 1, 6, 11 and 17. c Frequency
(x-axis) of structural variants observed in mammary tumours based on radiation quality, Trp53 genotype and tumour histology. ITX: intrachromosomal
translocation, INV: inversion rearrangements, INS: insertion rearrangements, DEL: deletion rearrangements, ANP: aneuploidy. Carcinomas have more SVs
than sarcomas from the same cohort of mice, and large inversions are enriched in tumours from Trp53+/− mice exposed to gamma radiation. d Incidence
of focal and non-focal genomic events in mammary tumours based on radiation quality, germline Trp53 genotype and tumour histology. A higher rate of
focal mutations (red and orange blocks) is observed in Fe-Ion associated carcinomas. Large non-focal structural variants (green and blue blocks) were
more prevalent in samples induced by gamma radiation. Mammary sarcomas have significantly fewer structural variants than mammary carcinomas from
the same cohorts of mice, independent of radiation quality and Trp53 genotype. e Distribution of structural variants identified in the same samples as in
c by size across the mouse genome. Size (y-axis) is shown by log scale. Chromosome number is shown along the bottom. Most SVs are small and less than
1 MB, as expected.
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gains (samples 2–5 on Supplementary Fig. 3 from top), losses
(samples MD5208B and MD5202A), or scrambled chromosomes
(sample M5215 A) in a manner reminiscent of previous analysis
of CNVs in radiation-induced lymphomas using Comparative
Genomic Hybridisation (CGH)35. Some chromosome regions
showed striking focal CNV gains, for example on proximal
chromosome 6.
To validate these observations, we carried out whole exome
sequencing (WES) of 56 additional radiation-induced tumours
comprising a wider range of histological types (Supplementary
Data 2). Combining both WGS and WES datasets, we confirmed
the gains of proximal chromosome 6 in mammary tumours
(Fig. 4). In contrast to these focal changes, lymphomas showed
characteristic whole chromosome 15 gains, regardless of germline
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Trp53 genotype or radiation quality. Chromosome 15 aneuploidy
has previously been found to be a common genetic event in
gamma radiation-induced lymphomas, and is thought to be
driven by cMyc35,43. These data demonstrate the tissue specificity
of genomic changes in tumours of distinct tissue and cellular
origins, even in the same individual animal and after exposure to
the same carcinogenic stimulus. While CNV analysis (Fig. 4)
showed numerous examples of whole chromosome aneuploidy,
defined as a contiguous region of gene copy number gains or
losses (see Methods section), other samples had chromosomes
with a mixed pattern comprising both gains and losses. The latter
phenomenon was significantly correlated with radiation quality as
85% of mixed chromosomes were associated with Fe-ion
exposure (P < 0.03). This is also consistent with the data above
showing that 56Fe-ion exposure is associated with increased focal
deletions and insertions, supporting a model in which 56Fe-ion
radiation causes direct focal damage in DNA, leading to double
strand breaks (DSB). There was also an association with tumour
type, as mammary tumours were strongly deletion biased (52%)
as compared to lymphoma (21%) or skin tumours (15%) (P <
2.9 × 10−3, chi-sq test).
Aside from chromosome 15 gains, the vast majority of
aneuploid chromosomes were observed in mammary tumours.
For example, loss of chromosome 4 was observed in 14 samples,
11 of which were mammary tumours. Chromosome 4 contains
Cdkn2a encoding the Ink4/Arf locus strongly implicated in cancer
pathogenesis with well-studied functional links to Trp53. Focal
loss of Cdkn2a is a common event in chemically induced mouse
tumours3, but such focal events were rarely detected in radiation-
induced tumours. This may suggest that other genes on
chromosome 4 are also driving the observed losses.
Met is a common target of amplification in heavy ion-induced
mammary carcinomas. The proximal region of chromosome 6
encompasses the Met oncogene, which was amplified in a total of
23 mammary tumour samples, 19 of which were induced by 56Fe-
ions and only 4 by gamma radiation (Fig. 5a, d). These data
suggested that the focal genomic events preferentially induced by
heavy ions select for mammary tumours driven by Met amplifi-
cation. RNASeq analysis of a subset of mammary tumours con-
firmed that amplification of the Met locus was indeed associated
with a large increase (>200 fold) in Met expression (Fig. 5c). A
functional contribution from other genes in the amplified region
which were also over-expressed, although not to the same level
(Supplementary Fig. 4A) is however also possible. The rearran-
gement hotspot on chromosome six overlapped the significantly
amplified region chromosome 6 cytoband A2, however the peak
region of structural rearrangements did not exactly overlap with
the Met gene (Fig. 5b). This is compatible with a model by which
complex structural SVs can lead to progressive rearrangements
and selection for increased copy number and expression of a
strong cancer driver such as the Met gene24.
Germline Trp53-dependent patterns of structural variants.
Chromothripsis, or chromosome-shattering, is a phenomenon
by which numerous clustered chromosomal rearrangements
occur in localised, confined genomic regions, first characterised
in human tumours and some congenital diseases. This process
has been attributed to a single catastrophic genetic event that
results in extensive DNA damage in the context of Trp53
dysfunction24,25,44–46. Chromothripsis is particularly associated
with tumour development in patients with Li-Fraumeni syn-
drome as they bear germline TP53 mutations22, but may also be
more generally associated with partial insufficiency in TP53 or
other genes linked to DNA damage responses such as ATM22,47.
While SVs were the predominant lesions observed in mouse
radiation-associated tumours, we also saw examples of whole or
partial chromosome chromothripsis. One mammary tumour
(MD5207c) showed strong evidence for whole chromosome
chromothripsis, with clusters of SVs across chromosome 1
(Fig. 6a, b). This mammary carcinoma was from a gamma-
exposed Trp53+/− mouse, and showed many of the hallmarks of
chromothripsis including chromosome wide translocations,
deletions and inversions, with several showing overlapping
breakpoints consistent with a simultaneous rather than sequential
event24.
Some carcinomas showed complex deletions on chromosome
11 overlapping Trp53 (Fig. 7a). In total, at least five carcinomas
showed focal clustered regions of SVs on chromosome 11, three
of which had variants clearly disruptive of the Trp53 locus.
The two other samples demonstrated focal clustering of SVs
on chromosome 11 which mapped close to but distal from Trp53
(Supplementary Fig. 5). Notably, CNV analysis of chromosome
11 identified distinct patterns of changes in tumours from
Trp53+/− and Trp53ΔPmice (Fig. 7b, top panel vs lower panels).
Tumours from Trp53+/− mice showed a higher frequency of
large scale or whole chromosome loss of chromosome 11,
regardless of radiation quality, as a common mechanism for
ensuring complete loss of Trp53 function (Fig. 7b). In contrast,
almost all changes of copy number at the Trp53 gene in tumours
from Trp53ΔP mice were seen in 56Fe-ion radiation-exposed
animals (Fig. 7c), suggesting that focal DNA damage of the type
induced by heavy ions is more likely to result in loss of Trp53 in
mice with this mutant allele, which is known to retain some
residual Trp53 function28.
Common driver events in radiation-induced tumours. Several
other potential driver genes in radiation-induced tumours were
identified by a combination of CNV analysis, exome sequencing
to identify point mutations, and gene expression (Supplementary
Data 3). One amplicon seen in several samples was on proximal
chromosome 9 in a region harbouring a family of genes encoding
matrix metalloproteinases (Mmps). MMPs can regulate the
tumour microenvironment, and their expression and activation is
increased in tumour tissue compared to normal48. Specific Mmp
genes, including Mmp 13, 12, 10 and 3, were highly expressed in
Fig. 4 The landscape of CNVs illustrate both focal and whole-chromosome events. a CNVs across all sequenced (whole exome and whole genome)
samples. Tumour samples are sorted by tissue site (large blocks separated by black lines) and subsequently by pathology, radiation quality and genotype
status of Trp53. Relative copy number states across each chromosome are indicated by a corresponding key as shown at the lower right. Some
chromosomes show predilection for whole-chromosomal amplification (e.g. Chromosome 5 and 15, the latter particularly in lymphomas) while other
regions show more deletions (Chromosome 4) or focal amplifications (e.g., proximal Chromosome 6 corresponding toMet in mammary samples). b Circos
plot illustrating relationships between amplification status, gene expression, translocations, and candidate driver genes across tumours induced by
radiation exposure. From outside to inside: 1. Driver genes. 2. Cytoband map of the mouse chromosome. 3. Focal CNVs gains. 4. Focal CNVs losses.
5. Aneuploidy gains. 6. Mixed chromosome changes. 7. Aneuploidy losses. 8. Expression of cancer driver genes in tumour samples versus normal samples.
9. Intrachromosomal and interchromosomal translocations identified in samples that were subjected to whole-genome sequencing. Y-chromosome was
not included in the analysis.
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tumours carrying the amplified region (Supplementary Fig. 4B).
However alternative candidates Birc2, Birc3 and Yap1, also
localised in the amplified region, showed some level of over-
expression and may also be functionally significant.
We also observed recurrent gene-level events in Notch1, a gene
known to play an important role in radiation-induced lymphoma
development49. In total, five lymphoma samples had distinct
Notch1 mutations. In two lymphomas, we found frameshift indels
in the PEST domain, resulting in activation of Notch signalling, as
well as multiple nonsynonymous SNVs in Notch1 (Supplemen-
tary Data 3 and 4). Unlike the indels, these were not limited to the
PEST domain and their functional implications are unclear. In
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two gamma radiation-induced lymphomas we found focal
amplification of Notch1, one of which also carried a point
mutation, demonstrating the multiplicity of mechanisms leading
to activation of Notch1 in radiation-induced lymphomas. Finally,
significant SNVs were found in a range of known driver genes
including Kras, Apc, Pten and hotspot sites in Trp53, the latter
examples occurring in tumours from the Trp53ΔP mice
(Supplementary Fig. 6 and Supplementary Data 3). The spectrum
of genomic alterations, both focal and large-scale, found in these
radiation-induced tumour samples is complex and reflects the
heterogeneity of genomic consequences resulting from radiation
exposure. The changes found over all samples is summarised in
the Circos plot in Fig. 4b.
Discussion
We have explored the impact of both high and low energy
radiation on tumour development in mice carrying two distinct
types of germline mutation in the Trp53 gene. Our data
demonstrate that tumours induced by both high and low LET
radiation exhibit the common features of low SNV burden, sig-
nificant genomic instability as shown by detection of large-scale
structural variants, and evidence of whole or partial chromosomal
chromothripsis. However, radiation quality had a significant
impact, together with germline Trp53 status, on the number and
types of tumours that developed, the overall survival of affected
mice, and the classes of genomic aberrations found by whole
genome and exome sequencing. The low SNV burden and high
indel/SNV ratio in mouse mammary tumours mirrors results
obtained by WGS analysis of a set of 12 human tumours that
were associated with prior exposure to radiotherapy4, but con-
trasts with the results obtained by analysis of tumours induced in
NF1-deficient mice by high dose fractionated ionising
radiation50,51. In the latter studies based on exome but not whole
genome sequencing, a much higher SNV burden was found,
including many recurrently mutated genes. However these data
are difficult to interpret because of the differences in the mouse
models used, the experimental design and methods of analysis,
which did not include filtering of SNVs through exactly matched
normal control DNA samples (see also Chang, H.-H. et al.52).
A surprising feature of our experiments, which evaluated the
effects of 50 cGy high or low LET radiation, was the exceptionally
high incidence of radiation-induced mammary cancers, com-
prising carcinomas and a range of sarcoma types including
angiosarcomas. Other models of radiation-induced tumour
development have not generally resulted in a high incidence of
mammary cancers. This could be due to the effects of higher
radiation dose (in the 2–5 Gy range) which is associated with
earlier onset haematologic malignancies and lymphomas. Alter-
natively, it could be due to a combination of dose and genetic
background, which could result in early death due to aggressive
lymphoma or sarcoma development before the time when sec-
ondary carcinomas would arise, as the median tumour free sur-
vival was 267 and 327 days for mammary and lung tumours while
it was only 130 days for lymphomas. This effect is further
accentuated in gamma-IR (40 day latency in lymphoma versus
331 days in mammary), which has been more frequently used in
historical studies. The present model therefore more closely
mimics susceptibility to human secondary breast cancer devel-
opment, which is known to be increased following radiation
exposure and to be influenced by both germline TP53 and
somatically acquired deficiency20,53–55.
High LET radiation appeared to be a more potent carcinogen
when compared to the same dose of gamma rays, causing early
onset tumours and increased tumour burden in the majority of
tissue types. While it should be cautioned that in the absence of a
dose-response evaluation one cannot ascertain the relative bio-
logical equivalence of the doses of gamma versus Fe-ion radiation
used in these experiments, these findings nevertheless agree with
prior work showing increased colon tumourigenicity induced by
Fe ions compared to gamma radiation in the APC/Min mouse
model56. Heavy-ion exposure was also associated with an
increased proportion of carcinomas, and despite equal numbers
of animals receiving the two radiation qualities, the incidence of
the two most commonly observed tumours (mammary and lung)
was significantly different for 56Fe-ions compared to gamma
radiation. Furthermore, Trp53 genotype impacts tumour histol-
ogy, as mice hemizygous for p53 were more likely to develop
sarcomas and spindle tumours, independent of radiation quality.
In contrast, the incidences of squamous cell carcinomas and
lymphomas were 10-fold and 5-fold higher, respectively, in
Trp53ΔP versus Trp53+/− mice (Fig. 1c).
Our data on the patterns of genomic alterations in these dif-
ferent tumour types may help to rationalise these observations.
On average, carcinomas exhibited higher numbers of complex
chromosome aberrations, while sarcomas that arose in the same
cohort of mice were genomically much more stable (Fig. 3c).
Heavy ion exposure was strongly associated with an increased
fraction of focal SVs, deletions and gene copy number changes
relative to gamma exposure, particularly in mice carrying the
Trp53ΔP allele. As a result, the Trp53ΔP genotype in combination
with 56Fe-ion exposure resulted in the highest incidence of gen-
omically unstable carcinomas. We conclude that heavy ion
radiation exposure is, on average, more likely to generate the level
of chromosomal instability required for transformation of the
appropriate cell of origin for carcinomas.
Over 60% of mammary tumours, regardless of germline Trp53
status, showed rearrangement and high-level amplification of the
Met locus on chromosome 6. These tumours were predominantly
induced by heavy ion radiation, which is compatible with the
genome-wide observation of increased focal genomic events
associated with exposure to 56Fe-ions. The propensity of heavy
ion radiation to induce focal DNA damage, together with a
specific feature of Met signalling in the mammary gland, may
select for common tissue specific activation of this pathway.
Several examples were observed of tumours with complex pat-
terns of whole chromosome or focal SVs, particularly in chro-
mosome 1 and focal regions on chromosomes 6, 11, and 17. These
features are similar to those generated by chromothripsis23 in
Fig. 5 Focal amplification ofMet is preferentially induced by 56Fe-ion radiation. aMammary tumours bear high frequency of focal amplifications on chr 6
(at the Met locus) predominantly in Fe-ion associated tumours. N= 42. b Focal analysis of the Met locus to illustrate that the same region with focal Met
amplifications are co-enriched for structural variants. The highest frequency of structural variants (red vertical line) does not coincide exactly with the
locus with the increased copy number of Met, suggesting that other selection mechanisms led to the high Met copy number. Locations of genes in the
amplified region are shown in the lower panel. N= 21 (translocations fromWGS data). N= 10 (expression from RNAseq data). c Higher expression ofMet
by whole transcriptome RNA-seq is strongly associated with copy number status. RNA from a total of 10 mammary tumours was sequenced. Expression is
shown for tumours with or without Met amplification, as well as matched normal samples. Error bars= 95% confidence intervals. d Association between
Met amplification and tumour site of origin (mammary, skin, lymphoma), histology and radiation quality.
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human tumours. A strong interaction between germline Trp53
status and radiation quality in determining the genomic changes in
tumours is exemplified by analysis of chromosome 11, which
harbours the Trp53 gene. The simplest way to lose Trp53 function
completely in Trp53+/− mice is to lose the wild type allele, by
chromosome non-disjunction, or by more focal events which can
be induced by heavy ion radiation (Fig. 7). The complete loss of
function in Trp53ΔPmice is less likely to occur due to the presence
of two partially functional alleles on different chromosomes.
Simple non-disjunction would not lead to loss of function, and we
only saw loss of Trp53ΔP alleles in tumours induced by 56Fe-ions
(Fig. 7), presumably due to the increased probability of focal DNA
damage at the Trp53 locus. These data emphasise the importance
of interactions between inherited germline alleles and environ-
mental exposures in determining tumour genome architecture.
Finally, our data shed light on a long-standing question
regarding mechanisms of DNA damage induced by ionizing
radiation. Double strand breaks can be generated by a direct
interaction between radiation particles and DNA, or indirectly by
generation of hydroxyl radicals, leading to formation of oxidised
bases and DNA single or double strand breaks. Deconvolution of
the mutational signatures in mammary tumours identified a
significant contribution from several known human signatures,
including signature 18 attributed to the generation of ROS39,40.
Although the absolute number of point mutations attributable to
this signature is relatively low, it was more prevalent in those
tumours induced by gamma exposure compared to high energy
56Fe-ions (P < 0.0318, Fig. 2b). High energy radiation, on the
other hand, is more likely to damage DNA directly causing
complex focal genomic changes leading to a higher level of
genetic instability and more aggressive tumours. While there are
some parallels between this work on mouse models and sequence
analysis of radiation-associated human cancers4, detailed com-
parisons will require a much more complete analysis of the
genetic alterations in human cancers that are more definitively
linked to radiation of different qualities and exposure levels.
Methods
Colony maintenance and breeding. The Trp53ΔP allele was initially maintained
on a mixed 129/SvJ and C57BL/6J background as has been described previously57.
We bred the Trp53ΔP allele from the mixed 129/Sv and C57BL/6 background onto
the FVB/N background with greater than 10 crosses resulting in 99.9% FVB/N
background for these mice. The Trp53(+/−) allele has been previously bred onto the
FVB background35. All mouse experiments received ethical approval by the Uni-
versity of California San Francisco Laboratory Animal Resource Centre. We have
complied with all relevant ethical regulations for animal testing and research.
Irradiation. To assess the effect of dose and compare HI to gamma radiation, we
exposed mixed (129/C57) and pure (FVB/N) background mice to radiation. Mice
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Fig. 6 Chromothripsis in radiation-induced tumours. a Mapping of different somatic mutation types across chromosome 1 in all of the whole genome
sequenced mammary tumours. Sub: Substitutions, ITX: Intrachromosomal translocation, INV: Inversion rearrangements, INS: Insertion rearrangements, DEL:
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were between 6 and 10 weeks of age. Mice exposed to HI radiation were subjected
to 29 cGy, 50 cGy, 81 cGy or 1 Gy of 600MeV/amu 56Fe-ions at a dose rate of
50 cGy/min delivered by a 20 × 20 cm beam. Gamma radiation consisted of 50 cGy
or 1 Gy of 137Cs gamma rays at a dose rate of 25 cGy/min. Irradiation was per-
formed at the Brookhaven national laboratory. Mice were shipped from UCSF to
Brookhaven National Laboratories and rested for at least 3 day prior to whole-body
irradiation. Following irradiation, mice were returned to UCSF for monitoring.
Sham irradiated mice were flown to Brookhaven but were not irradiated.
Tumour analysis and pathology. Mice were monitored for the development of
tumours at UCSF by both visual evaluation and palpation for a minimum of
500 days, until the mouse body-condition score deteriorated, or a tumour exceeded
1 cm in diameter.
At the time of sacrifice radiosensitive tissues including the skin, mammary,
thymus and spleen were harvested along with the tumour and the tail as a non-
radiation sensitive control. A small section of each tissue was preserved for
histology and the remainder was frozen for DNA, RNA or protein extraction. H&E
slides were prepared from tumour samples and examined by a board-certified
pathologist to determine histological subtypes. Tumours were categorised based on
histology and disease site at time of necropsy. Mammary tumours include
carcinomas, spindle cell tumours, sarcomas and angiosarcomas, the latter which
was verified by immunohistochemistry (CD31+). To accurately represent the
range of mammary tumours identified, whole exome sequencing analysis was
performed on all mammary tumour types. Only carcinomas and sarcomas
(angiosarcomas were excluded) were used for whole genome sequencing.
DNA and RNA extraction. DNA was extracted from snap frozen tumour tissues
using the Qiagen DNAeasy kit as per manufacturer’s instructions. Concentration
and quality were determined by Nanodrop spectrophotometry and by PicoGreen
(Invitrogen). RNA was extracted from snap frozen tissues using the Zymo Quick-
RNA column purification kit. RNA concentration and quality were determined by
Nanodrop and Agilent RNA Nano Bioanalyzer kit.
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Fig. 7 Interaction between Trp53 genotype and RT quality in complex structural variants. a Three samples showing representative enrichment of SVs on
chromosome 11 near the Trp53 locus, some with evidence of co-localisation of breakpoints and/or variants. Arrows denote the location of the Trp53 gene
along chromosome 11. b Tumours from Trp53+/− mice show common non-focal deletions or whole-chromosomal aneuploidy in chr 11 (top panel). These
large scale copy number alterations are less common in tumours from the Trp53ΔP mice (lower panels). Arrow denotes the location of Trp53. c Effect of
Trp53 germline genotype on patterns of somatic alterations at the Trp53 gene in mammary tumours. Trp53 deletions are frequently observed in animals of
Trp53 heterozygous background exposed to either Fe ions or gamma radiation. In Trp53ΔP mice, localised deletions at the Trp53 locus were only seen in
tumours induced by 56Fe ions.
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Whole exome sequencing. Exonic DNA was captured using the Agilent whole
exome capture kit (SureSelect Mouse All Exon). Captured material was indexed
and sequenced on the Illumina platform at the Wellcome Trust Sanger Institute at
an minimum depth of 100×. Raw 75 bp pair end sequencing reads were aligned
with BWA-aln (v0.5.10)b58 to the GRCm38 mouse reference genome and were
subsequently realigned around known InDels using GATK InDel re-aligner (v1.5-
9) producing a single Binary Alignment Mapping (BAM) file for each sample.
Whole genome sequencing. DNA was sheared to 450 bp fragment size using a
Covaris S2. A single Illumina TruSeq v3 sequencing library was created for each
strain according to manufacturer’s protocols. Each library was sequenced on a HiSeq
2000 over four lanes. Sequencing reads from each lane were aligned to the C57BL/6 J
GRCm38 (mm10) mouse reference genome using BWA-MEM (0.7.13). For each
library, aligned reads from each lane were merged using Picard Tools (v1.64)
resulting in a single BAM file for each sample with a median coverage of 39×.
SNV analysis. SNV calling for exomes was performed using MuTect (version 1.1.6)59.
Tumour samples were called against two genotype and strain matched controls and
filtered for quality. The following filters were used: minimum of 10 q20 or greater
covering bases in both tumour and normal, minimum tumour alternate allele fraction
of 0.2, minimum of 3 alternate alleles in tumour, no more than 3 alternate alleles in
either normal. Variants were also filtered for known variation using the Sanger variant
dataset (mgp.v3.snps.rsIDdbSNPv137, filtered to exclude wild mice and all variants with
q less than 20), and a pooled set of variants and variable regions observed in all control
samples (called by MuTect2 version 3.6)59.
Evaluating the result revealed the existence of a large number of likely germline
variants in non-coding regions. To remove these variants, we selected all variants
that were exactly replicated (same location, same alternate allele) in at least three
samples without a consequential coding effect. In all cases these variants appeared
to be approximately heterozygous, and no variant was consequential. As a result,
we omitted all variants exactly replicated in three or greater samples without an
effect on protein sequence, and all variants exactly replicated seven or more times
without regard to context.
Initial analysis revealed the existence of a large number of variants with the
motif GGTGN. These sites were overwhelmingly associated with T > G
transversions resulting in a GGGG homopolymer. Sanger sequencing showed that
the majority of these variants were false positives. We imposed an additional,
substantially more stringent, set of filters for these sites: minimum of 50 q20 or
greater covering bases in both tumour and normal, minimum tumour alternate
allele fraction of 0.2, minimum of 15 alternate alleles in tumour, normal alternate
allele fraction of no greater than 0.05. This dramatically reduced the influence of
this artifact. After this filtration, we took the intersection of the pass-filter variants
between both controls as the keeper set for each tumour.
For WGS. somatic variants were detected using CaVEMan, an expectation
maximisation–based somatic substitution detection algorithm60. Detected somatic
variants were then filtered using an array of quality filters and commonmouse genome
variants were excluded. Tumours were called against paired tail DNA and filtered for
the following; greater than or equal to 10 q20 or more bases, alternate allele fraction
greater than 0.1 in tumour, and alternate allele fraction less than 0.1 in normal. In
addition, we removed all variants occurring in simple repeat regions (simpleRepeat.txt,
downloaded from hgdownload.cse.ucsc.edu/goldenpath/mm10/database/)61.
Indel analysis. Indel calling in exome samples was performed using pindel (ver-
sion 0.2.4w;62). Samples were called against two normal with the following options:
-l false –x 1 –M 4. Results were then filtered for germline events, recurrence, and
simple repeats. Germline filtration was accomplished by identifying all sites found
in controls in this cohort and flagging any tumour indel that overlapped (within 2
bases) these sites. We also repeated this strategy for germline events found in the
Sanger list of indel events (mgp.v3.indels.rsIDdbSNPv137, filtered for minimum
quality 20 and no variants present only in wild derived strains).
We noticed a large degree of exact recurrence of indels within the tumour
cohort, even following germline filtration. After manual examination, we
determined the majority of these variants were likely to be germline or the result of
recurrent sequencing/calling artifacts. To remove these variants, we removed all
non-consequential indels that were exactly replicated (same location and alternate
allele) in 3 or more samples. We also flagged regions (50 bp windows) containing
three or more indels of any type. Manual evaluation of these regions revealed them
to be primarily artefactual, with a small number of potentially biologically
meaningful sites. As the number of artefactual variants substantially outnumbered
the number of biologically meaningful sites, we omitted these regions for the
calculation of indel rates but included them for the analysis of functional impact on
cancer associated genes. We also removed all exome indels in simple repeat regions.
Indels were called in whole-genome samples by comparing tumour to paired
control tail DNA using a modified version of the pindel programme62. Resulting
lesions were then filtered for exact and regional recurrence (more than three exact
replicates or indels within 50 bp across the tumour cohort), and presence within
simple repeat regions. Indel rates were defined similar to SNVs.
Mutation signature analysis. The mutational catalogues from the 21 WGS
samples were analyzed for mutational signatures. Signature extraction was per-
formed using SigProfiler (conducted using methods based on nonnegative matrix
factorisation (NMF) as described in Alexandrov et al. (refs. 1,36,37)). Analyses were
carried out separately for single base substitutions (SBS signatures) and indels (ID
signatures). We first performed de novo mutation signature extraction using NMF-
based method as described in SigProfiler.
For SBS signatures, extracted signatures were then compared to the set of
mutational signatures deciphered from the COSMIC database as previously
described (refs. 1,36,37). The algorithm identifies the optimal combination of known
human signatures that explains the observed mutation patterns (highest cosine
similarity). All signatures extracted across all samples were able to be explained by
a combination of signatures from the known human signatures (cosine similarity >
0.75) and thus we did not identify any signatures that would be considered novel.
We performed hierarchical clustering of the samples based on the relative
contribution of identified mutation signatures using both results from the de novo
extraction and after signature deconvolution.
For INDELs, given the limited understanding for these signatures, particularly
in mouse, as well as the fact that there were very few mutations, we chose to
perform downstream analysis using only the de novo extracted signatures.
Code for the original SigProfiler software is available: https://www.mathworks.
com/matlabcentral/fileexchange/38724-sigprofiler.
For further details of this algorithm and it’s most up to date implementation
we refer the reader to ref. 1 and the updated software webpage: https://pypi.org/
project/sigprofiler/.
CNV segmentation and analysis. CNV segmentation in exomes was performed
using CNVkit63 following the default workflow with target regions defined from
the UCSC refgene flatfile gene locations padded by +/−500 basepairs.
To remove spuriously aberrant regions we assessed control copy-number
profiles for aneuploidies. Any region found to be aberrant in two or more controls
was omitted from the tumour samples.
CNV segmentation in whole-genome samples was performed using BICseq
(version 1.1.2;64) with the following options: --paired --I= 400,50 --bin_size= 250.
Three samples showed consistently patterned aneuploidies that appeared to be
artefactual and were omitted (MD5215a, MD5212a, MD5210a).
Amplification was defined as a copy-number log2 ratio over 0.15, and deletion
as log2 ratio less than −0.15. A whole-chromosome amplification was defined as
greater than 50% of the chromosome covered by copy-number bins, and greater
than 40% of the chromosome called as amplified. Whole-chromosome deletions
were defined with similar proportions. Mixed chromosomes were chromosomes
that fit the definition of amplification or deletion, but with 5% or more of the
chromosomes total length aneuploid in the opposite direction. This definition
captured the majority of the visibly mixed chromosomes without including any
discernable false positives.
Significantly recurrent whole-chromosome aneuploidies were identified by first
permuting chromosome state per sample 1000 times, counting the maximum
observed quantity of aneuploidies per chromosome in the randomised data, and
identifying the threshold that was greater than 95% of observed maximum
aneuploidy counts in the permuted data. This was done for any aneuploidy,
amplifications only, and deletions only.
Focal amplifications and deletions were identified through the cghMCR
package65 with amplification and deletion thresholds increased to +/−0.25 to focus
on high-level aneuploidies. Significance threshold was defined by 1000
permutations as above.
Rearrangement analysis. Rearrangements were called using both lumpy66 and
breakdancer67 but only breakdancer calls were used due to extremely high agree-
ment between the intrachromosomal events from both callers, and the high level of
spurious interchromosomal rearrangements identified by lumpy. These spurious
calls appeared to corroborate recent findings showing that lumpy performed poorly
when calling non-C57B6 samples against the C57BN6 genome68. Breakdancer was
used with the following arguments: -r 10 –q 30.
Rearrangements were filtered by depth and region. Depth filters included the
following: less than 2 control reads, and greater than or equal to 10 tumour reads.
Regional filters included simple repeats and mapability. Mapability was defined as
uniquely mapping from the crgMapabilityAlign50mer.txt file for the mm9 genome
(downloaded from hgdownload.cse.ucsc.edu/goldenpath/mm9/database)
remapped to mm10 with liftOver61. Any rearrangement with either endpoint
within a simple repeat or non-uniquely mapping region was omitted.
Focal rearrangement hotspots were identified by establishing the intermutation
distance (the distance between any given rearrangement and its nearest neighbour) in
1Mb windows sliding by 100 kb intervals. Enriched sites were defined as those windows
with intermutation distance greater than five standard deviations greater than the
genome-wide mean, with at least six unique lesions, in at least three different samples.
Statistical analysis and plotting. Statistical analysis was performed in R (version
3.3.3)69. Two-group analyses were performed using the non-parameteric Mann-
Whitney U test. Fisher’s test was used to assess categorical data. The glm function
was used to model the relationship between whether or not a chromosome was
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aneuploid and genotype/radiation exposure. Survival analysis was performed using
Cox proportional hazards modelling and significance evaluated by the log-rank
test. Plots were generated using the ggplot2 package70.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
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